This invention pertains to methods for treating atrial tachyarrhythmias such as atrial fibrillation. In particular, the invention relates to an apparatus and method for treating atrial fibrillation by ablation therapy.
Fibrillation refers to a condition in which muscle fibrils enter a state of extremely rapid, small-scale contractions that do not coordinate to effect contraction of the muscle as a whole. When this occurs in the left ventricle, the heart chamber responsible for pumping blood into the arterial vasculature, it is serious and rapidly fatal. When it occurs in the musculature of the atria, it is less immediately serious and not necessarily fatal. It is still important to treat atrial fibrillation, however, for several reasons. First, atrial fibrillation is associated with a loss of atrio-ventricular synchrony which can be hemodynamically compromising and cause such symptoms as dyspnea, fatigue, vertigo, and angina. Atrial fibrillation can also predispose to strokes resulting from emboli forming in the left atrium. Although drug therapy, in-hospital cardioversion, and implantable cardioverter/defibrillators are acceptable treatment modalities for atrial fibrillation, a curative approach such as ablation therapy offers a number of advantages to certain patients, including convenience and greater efficacy.
Electrical ablation therapy treats cardiac arrhythmias by destroying myocardial tissue involved in the initiation or maintenance of the tachyarrhythmia. Ablation is most often accomplished by delivering radiofrequency electrical energy through a catheter electrode that has been placed next to the tissue to be destroyed. One way that the technique has been employed in order to treat atrial fibrillation is to identify ectopic sites or reentrant pathways electrophysiologically and then eliminate them by radiofrequency catheter ablation. Recent evidence has shown that the great majority of paroxysms of atrial fibrillation are initiated by trains of rapid discharges originating from the pulmonary veins. Accordingly, catheter techniques have been developed for ablating these sites with radiofrequency energy applied from within the pulmonary veins, but electrophysiological mapping of such sites is difficult. Alternatively, another technique involves the production of a circumferential ablation lesion within a pulmonary vein in order to block the conduction pathway from the vein to the left atrium. An effective circumferential lesion must be completely continuous, however, and this means that the ablation device must be precisely located within the vein or ostium, which may be difficult to accomplish. Furthermore, a common complication of this procedure is pulmonary venous stenosis resulting from scarring within the pulmonary vein which has variable clinical consequences.
An objective of the present invention is to provide an improved apparatus and method for pulmonary vein ablation in order to treat atrial fibrillation. In accordance with the invention, a stent catheter having a stent mounted thereon is introduced into the left atrium of a patient. The stent is deployed by expansion of the stent within a pulmonary vein or ostium of the vein. The stent expansion may be performed with a balloon at the distal end of the stent catheter or by a self-expanding stent. Tissue surrounding the deployed stent is then ablated to stop discharges from ectopic foci in the vein from reaching the left atrium. After the ablation, the stent is left in place in order to prevent stenosis of the vein.
In order to produce the ablation, radiofrequency energy is transmitted into the surrounding tissue by means of a catheter making contact with the stent which then causes heating of the surrounding tissue. The stent may have electrodes for transmitting current to the surrounding tissue or the stent itself may be used as an electrode. The ablation lesions in the tissue surrounding the stent may be selectively produced so as to destroy one or more ectopic foci, or a circumferential lesion may be produced that interrupts a conduction pathway between the vein and the left atrium.
As noted above, it has been found that the ectopic foci responsible for most episodes of atrial fibrillation are found in the pulmonary veins. The pulmonary veins empty into the left atrium, and a myocardial muscle sleeve extends over the proximal segment of the veins. The myocytes in these pulmonary vein sleeves, unlike ordinary atrial myocytes, exhibit spontaneous activity and can thus constitute ectopic sites responsible for initiating and maintaining atrial fibrillation. In order to block the discharges from these myocytes with ablation therapy, either the myocytes themselves are destroyed or an ablation lesion is made that destroys excitable tissue in the pathway leading from the myocytes to the left atrium.
Shown in
The stent catheter 100 with the stent 110 fixed thereon may be positioned in a pulmonary vein using an over the wire catheterization technique in which a radio-opaque catheter, or guidewire over which the catheter slides, is passed into a patient's vascular system under fluoroscopic guidance. Vascular access is obtained by puncturing a vessel and seating a hemostatic valve within the puncture wound. The stent catheter is then passed into the patient's vascular system through the valve. In one approach, the catheter is introduced into a peripheral vein and then advanced through the vena cava and into the right atrium. From there, the catheter is positioned against the fossa ovalis in the atrial septum, and a needle or trochar is advanced distally through a lumen of the stent catheter and out the distal end to puncture the fossa ovalis. The catheter is then passed through the atrial septum to reach the left atrium and gain access to the pulmonary veins. In another approach, the catheter is advanced into the left atrium from the arterial system by accessing a peripheral artery and advancing the catheter into the aorta, around the aortic arch, into the left ventricle, and then into the left atrium through the mitral valve. With either approach, after reaching the left atrium, the distal end of the stent catheter 100 is advanced into a selected pulmonary vein to position the stent 110 within either the vein or the ostium of the vein where the conduction block is to be formed. Alternatively, the stent deployment could be done during open-heart surgery or a transthoracic surgical procedure. In that case, rather than a catheter, a plunger-type instrument could be used to deploy the stent and apply energy thereto to produce the ablation lesion. Saline infusion for cooling could also be applied through the plunger type instrument.
The stent 110 is deployed by expanding the stent within the vein by, for example, inflating balloon 120 over which the stent 110 is fitted. Tissue surrounding the deployed stent is then ablated so as to stop discharges from ectopic foci in the vein from reaching the left atrium. The ablation lesions in the tissue surrounding the stent may be selectively produced so as to destroy one or more ectopic foci, or a circumferential lesion may be produced that interrupts a conduction pathway between the vein and the left atrium. After the ablation lesion has been produced, the stent is left in place in order to prevent stenosis of the vein as a result of fibrosis and scarring.
In order to produce the ablation lesion, radiofrequency energy is applied to the stent which causes thermal heating of the surrounding tissue. The result is either a circumferential conduction block around the vein which isolates myocytes in the vein distal to the lesion or localized destruction of ectopic foci. Such energy can be applied from the stent catheter or from a separately introduced ablation catheter which contacts the stent and transmits electrical energy thereto.
The stent itself may be used as an electrode or may have separate electrodes for transmitting current to the surrounding tissue. In the former case, the stent may be made of any electrically conductive material such as platinum, silver, gold, stainless steel, nitinol, or titanium.
Separate electrodes on the stent may be of the same material or a separate material which may be formed on the stent by, for example, sputter coating or vapor deposition.
In order to reduce the risk of thrombus formation, a coating of heparin or other anti-coagulant can be applied to the stent before deployment. In addition, mechanical anchoring devices may be incorporated into the stent in order to prevent dislodgement after the stent is deployed.
During the ablation procedure, it may be useful to monitor the temperature of the tissue as it is heated by the ablation electrodes. Accordingly,
As described above, using a deployed vascular stent as a vehicle for delivering ablation energy to a selected location greatly facilitates the ablation procedure and produces more consistent results. In the event a first ablation procedure is not satisfactory, however, having the stent already deployed also allows any repeat ablation procedures to be more easily performed.
Although the invention has been described in conjunction with the foregoing specific embodiment, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.
This application claims the benefit of U.S. Provisional Application No. 60/298,738, filed on Jun. 15, 2001, under 35 U.S.C. 119(e).
Number | Name | Date | Kind |
---|---|---|---|
3692027 | Ellinwood, Jr. | Sep 1972 | A |
4003379 | Ellinwood, Jr. | Jan 1977 | A |
4146029 | Ellinwood, Jr. | Mar 1979 | A |
4281664 | Duggan | Aug 1981 | A |
4299220 | Dorman | Nov 1981 | A |
4544371 | Dormandy, Jr. et al. | Oct 1985 | A |
4556063 | Thompson et al. | Dec 1985 | A |
4686987 | Salo et al. | Aug 1987 | A |
4871351 | Feingold | Oct 1989 | A |
4897987 | Spaila | Feb 1990 | A |
4944299 | Silvian | Jul 1990 | A |
4987897 | Funke | Jan 1991 | A |
5040533 | Fearnot | Aug 1991 | A |
5041107 | Heil, Jr. | Aug 1991 | A |
5042497 | Shapland | Aug 1991 | A |
5058581 | Silvian | Oct 1991 | A |
5087243 | Avitall | Feb 1992 | A |
5127404 | Wyborny et al. | Jul 1992 | A |
5190035 | Salo et al. | Mar 1993 | A |
5220917 | Cammilli et al. | Jun 1993 | A |
5269301 | Cohen | Dec 1993 | A |
5284136 | Hauck et al. | Feb 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5342408 | deCoriolis et al. | Aug 1994 | A |
5353800 | Pohndorf et al. | Oct 1994 | A |
5368028 | Palti | Nov 1994 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5416695 | Stutman et al. | May 1995 | A |
5456692 | Smith, Jr. et al. | Oct 1995 | A |
5460605 | Tuttle et al. | Oct 1995 | A |
5496360 | Hoffmann et al. | Mar 1996 | A |
5499971 | Shapland et al. | Mar 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5556421 | Prutchi et al. | Sep 1996 | A |
5562713 | Silvian | Oct 1996 | A |
5579876 | Adrian et al. | Dec 1996 | A |
5586556 | Spivey et al. | Dec 1996 | A |
5607418 | Arzbaecher | Mar 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5634899 | Shapland et al. | Jun 1997 | A |
5662689 | Elsberry et al. | Sep 1997 | A |
5690682 | Buscemi et al. | Nov 1997 | A |
5693075 | Plicchi et al. | Dec 1997 | A |
5720770 | Nappholz et al. | Feb 1998 | A |
5730125 | Prutchi et al. | Mar 1998 | A |
5800498 | Obino et al. | Sep 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5817131 | Elsberry et al. | Oct 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
5893881 | Elsberry et al. | Apr 1999 | A |
5899928 | Sholder et al. | May 1999 | A |
5925066 | Kroll et al. | Jul 1999 | A |
5949659 | Lesche | Sep 1999 | A |
5954761 | Macheck et al. | Sep 1999 | A |
5967986 | Cimochowski et al. | Oct 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5980566 | Alt et al. | Nov 1999 | A |
5991668 | Leinders et al. | Nov 1999 | A |
6016447 | Juran et al. | Jan 2000 | A |
6016448 | Busacker et al. | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6115636 | Ryan | Sep 2000 | A |
6140740 | Porat et al. | Oct 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6154675 | Juran et al. | Nov 2000 | A |
6168801 | Heil, Jr. et al. | Jan 2001 | B1 |
6179789 | Tu et al. | Jan 2001 | B1 |
6198394 | Jacobsen et al. | Mar 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6206914 | Soykan et al. | Mar 2001 | B1 |
6213942 | Flach et al. | Apr 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6237398 | Porat et al. | May 2001 | B1 |
6251109 | Hassett et al. | Jun 2001 | B1 |
6254573 | Haim et al. | Jul 2001 | B1 |
6277078 | Porat et al. | Aug 2001 | B1 |
6298272 | Peterfeso et al. | Oct 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6317615 | KenKnight et al. | Nov 2001 | B1 |
6358202 | Arent | Mar 2002 | B1 |
6361522 | Scheiner et al. | Mar 2002 | B1 |
6361780 | Ley et al. | Mar 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6443949 | Altman | Sep 2002 | B2 |
6453195 | Thompson | Sep 2002 | B1 |
6459917 | Gowda et al. | Oct 2002 | B1 |
6501983 | Natarajan et al. | Dec 2002 | B1 |
6511477 | Altman et al. | Jan 2003 | B2 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6518245 | Anderson et al. | Feb 2003 | B1 |
6519488 | KenKnight et al. | Feb 2003 | B2 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6632223 | Keane | Oct 2003 | B1 |
6645145 | Dreschel et al. | Nov 2003 | B1 |
6662045 | Zheng et al. | Dec 2003 | B2 |
6716242 | Altman | Apr 2004 | B1 |
20010000802 | Soykan et al. | May 2001 | A1 |
20020026228 | Schauerte | Feb 2002 | A1 |
20030004403 | Drinan et al. | Jan 2003 | A1 |
20030069606 | Girouard et al. | Apr 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
Number | Date | Country |
---|---|---|
0054138 | Jun 1982 | EP |
1050265 | Nov 2000 | EP |
WO 9733513 | Sep 1997 | WO |
Number | Date | Country | |
---|---|---|---|
20030018362 A1 | Jan 2003 | US |
Number | Date | Country | |
---|---|---|---|
60298738 | Jun 2001 | US |